Company intelligence / Profile preview

Tucuvi

Ownership: Private
Development stage: Other

Overview

Tucuvi’s clinically validated conversational AI platform, LOLA®, automates routine clinical phone calls for patient monitoring and follow-up. It has demonstrated high adherence rates (>90% in some studies), improved continuity of care, and operational efficiency across multiple indications such as prostate cancer and malignant bowel obstruction. The solution has been recognized in scientific publications and by leading healthcare organizations for its impact on workflow optimization and patient outcomes

Therapeutic areas: CardiovascularOncologyOther
Modalities: Non-pharmacological therapy
Industry: Digital Health Medical Devices

Partnerships

AstraZeneca (collaboration on heart failure/cardiology with Vall d'Hebron University Hospital)

Beyond the preview

Go deeper on Tucuvi.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tucuvi.

Explore the full profile